Tags

Type your tag names separated by a space and hit enter

Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine.
Gene Ther 2012; 19(1):78-85GT

Abstract

The ability of transient immunosuppression with a combination of a non-depleting anti-CD4 (NDCD4) antibody and cyclosporine (CyA) to abrogate immune reactivity to both adeno-associated viral vector (AAV) and its transgene product was evaluated. This combination of immunosuppressants resulted in a 20-fold reduction in the resulting anti-AAV8 antibody titres, to levels in naïve mice, following intravenous administration of 2 × 10(12) AAV8 vector particles per kg to immunocompetent mice. This allowed efficient transduction upon secondary challenge with vector pseudotyped with the same capsid. Persistent tolerance did not result, however, as an anti-AAV8 antibody response was elicited upon rechallenge with AAV8 without immunosuppression. The route of vector administration, vector dose, AAV serotype or the concomitant administration of adenoviral vector appeared to have little impact on the ability of the NDCD4 antibody and CyA combination to moderate the primary humoral response to AAV capsid proteins. The combination of NDCD4 and CyA also abrogated the humoral response to the transgene product, that otherwise invariably would occur, following intramuscular injection of AAV5, leading to stable transgene expression. These observations could significantly improve the prospects of using rAAV vectors for chronic disorders by allowing for repeated vector administration and avoiding the development of antibodies to the transgene product.

Authors+Show Affiliations

Department of Haematology, UCL Cancer Institute, University College London, Oxford, UK.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21716299

Citation

McIntosh, J H., et al. "Successful Attenuation of Humoral Immunity to Viral Capsid and Transgenic Protein Following AAV-mediated Gene Transfer With a Non-depleting CD4 Antibody and Cyclosporine." Gene Therapy, vol. 19, no. 1, 2012, pp. 78-85.
McIntosh JH, Cochrane M, Cobbold S, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther. 2012;19(1):78-85.
McIntosh, J. H., Cochrane, M., Cobbold, S., Waldmann, H., Nathwani, S. A., Davidoff, A. M., & Nathwani, A. C. (2012). Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Therapy, 19(1), pp. 78-85. doi:10.1038/gt.2011.64.
McIntosh JH, et al. Successful Attenuation of Humoral Immunity to Viral Capsid and Transgenic Protein Following AAV-mediated Gene Transfer With a Non-depleting CD4 Antibody and Cyclosporine. Gene Ther. 2012;19(1):78-85. PubMed PMID: 21716299.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. AU - McIntosh,J H, AU - Cochrane,M, AU - Cobbold,S, AU - Waldmann,H, AU - Nathwani,S A, AU - Davidoff,A M, AU - Nathwani,A C, Y1 - 2011/06/30/ PY - 2011/7/1/entrez PY - 2011/7/1/pubmed PY - 2012/4/26/medline SP - 78 EP - 85 JF - Gene therapy JO - Gene Ther. VL - 19 IS - 1 N2 - The ability of transient immunosuppression with a combination of a non-depleting anti-CD4 (NDCD4) antibody and cyclosporine (CyA) to abrogate immune reactivity to both adeno-associated viral vector (AAV) and its transgene product was evaluated. This combination of immunosuppressants resulted in a 20-fold reduction in the resulting anti-AAV8 antibody titres, to levels in naïve mice, following intravenous administration of 2 × 10(12) AAV8 vector particles per kg to immunocompetent mice. This allowed efficient transduction upon secondary challenge with vector pseudotyped with the same capsid. Persistent tolerance did not result, however, as an anti-AAV8 antibody response was elicited upon rechallenge with AAV8 without immunosuppression. The route of vector administration, vector dose, AAV serotype or the concomitant administration of adenoviral vector appeared to have little impact on the ability of the NDCD4 antibody and CyA combination to moderate the primary humoral response to AAV capsid proteins. The combination of NDCD4 and CyA also abrogated the humoral response to the transgene product, that otherwise invariably would occur, following intramuscular injection of AAV5, leading to stable transgene expression. These observations could significantly improve the prospects of using rAAV vectors for chronic disorders by allowing for repeated vector administration and avoiding the development of antibodies to the transgene product. SN - 1476-5462 UR - https://www.unboundmedicine.com/medline/citation/21716299/Successful_attenuation_of_humoral_immunity_to_viral_capsid_and_transgenic_protein_following_AAV_mediated_gene_transfer_with_a_non_depleting_CD4_antibody_and_cyclosporine_ L2 - http://dx.doi.org/10.1038/gt.2011.64 DB - PRIME DP - Unbound Medicine ER -